Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

170.81
+2.651.58%
Post-market: 170.80-0.0100-0.01%19:59 EDT
Volume:7.05M
Turnover:1.20B
Market Cap:44.07B
PE:-12.01
High:171.04
Open:167.73
Low:167.52
Close:168.16
52wk High:176.60
52wk Low:141.05
Shares:258.02M
Float Shares:258.02M
Volume Ratio:0.84
T/O Rate:2.73%
Dividend:2.45
Dividend Rate:1.43%
EPS(TTM):-14.2170
EPS(LYR):-14.2170
ROE:-9.22%
ROA:1.03%
PB:1.28
PE(LYR):-12.01

Loading ...

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Is Ping An Healthcare And Technology (SEHK:1833) Undervalued After Its GlobalCare Launch?

Simply Wall St.
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Amid Inflation Data Release

MT Newswires Live
·
Sep 30

LIVE Markets-TD Cowen Says AI Promises Hospitals a Margin Cure

Reuters
·
Sep 30

Pharming Group: Buy Rating Maintained and Strategy Intact Despite Surprise CEO Departure; Price Target Reaffirmed at $38

TIPRANKS
·
Sep 30

LIVE Markets-Cooler than Expected PCE Adds Some Steam to US Stock Futures

Reuters
·
Sep 30

Health Care Select Sector SPDR: Pivot points

TIPRANKS
·
Sep 30

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Sep 30

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Sep 30

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Sep 30

Merck & Co - no Serious or Opportunistic Infections Observed in Study

THOMSON REUTERS
·
Sep 30

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Sep 30